A Phase II Trial of Bryostatin-1 in Hypernephroma
OBJECTIVES: I. Determine the response rates in patients with progressive hypernephroma
treated with bryostatin 1. II. Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive bryostatin 1 IV over 24 hours on days
1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. For patients with stable or
responding disease after completion of course 2, treatment repeats every 4 weeks in the
absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study within 12-18
Primary Purpose: Treatment
Adrian L. Harris, MD
Oxford Radcliffe Hospital
United States: Federal Government